Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis

Company Overview

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its products include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia, and acute skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. It also has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. The company was founded in 1996 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $2.23 to $2.23
• 50-Day Range: $2.17 to $2.23
• 52-Week Range: $1.29 to $3.65
• Volume: N/A
• Average Volume: 724,253 shs
• Market Capitalization: $127.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PRTK Stock Analysis - Frequently Asked Questions

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company earned $24.45 million during the quarter, compared to the consensus estimate of $22.98 million.

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Paratek Pharmaceuticals investors own include Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), Verastem (VSTM), Citius Pharmaceuticals (CTXR), SCYNEXIS (SCYX) and Aurinia Pharmaceuticals (AUPH).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 6/03/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:PRTK
• Previous Symbol: NASDAQ:TSPT
• CIK: 1178711
• Web: www.paratekpharma.com
• Phone: (617) 807-6600
• Fax: 617-275-0039
• Employees: 268
• Year Founded: 1996

Profitability

• EPS (Most Recent Fiscal Year): ($1.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$63.57 million
• Net Margins: -35.44%
• Pretax Margin: -35.35%
• Return on Equity: N/A
• Return on Assets: -40.05%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.52
• Quick Ratio: 0.46

Sales & Book Value

• Annual Sales: $160.27 million
• Price / Sales: 0.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.08) per share
• Price / Book: -0.72

Miscellaneous

• Outstanding Shares: 57,320,000
• Free Float: 52,736,000
• Market Cap: $127.82 million
• Optionable: Optionable
• Beta: 1.70